Literature DB >> 7646915

No standard treatment is available for advanced pancreatic cancer.

R Lionetto1, V Pugliese, P Bruzzi, R Rosso.   

Abstract

All randomised trials, published from 1980 to 1993, of treatments in advanced and locally unresectable exocrine pancreatic carcinoma were critically reviewed to identify the most effective therapeutic strategy for use as a control arm in randomised trials for such patients. All the published randomised trials on patients with pancreatic cancer were identified, and the treatment results summarised by means of published methodological guidelines. Twenty-seven reports, including 21 on hormonal or chemotherapy and six on radio/chemotherapy were identified. Very different treatment programmes were used in the trials, without a rationale sequence for testing hypotheses. Furthermore, several methodological drawbacks undermined both the internal and the external validity of these studies. Therefore, no meta-analysis can be conducted, combining the results of the randomised controlled trials in pancreatic cancer published from 1990 to 1993; no standard treatment is currently available for patients with advanced pancreatic cancer; future studies should screen new drugs or new combinations; and an untreated control group should be included in future comparative studies until real advantages in terms of better quality of life or improved survival are demonstrated.

Entities:  

Mesh:

Year:  1995        PMID: 7646915     DOI: 10.1016/0959-8049(94)00445-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction.

Authors:  Zhengfa Mao; Xiaoyan Ma; Xin Fan; Lei Cui; Ting Zhu; Jianguo Qu; Jianxin Zhang; Xuqing Wang
Journal:  Tumour Biol       Date:  2014-07-16

Review 3.  [Therapy of pancreatic adenocarcinoma].

Authors:  M Böhmig; B Wiedenmann; S Rosewicz
Journal:  Med Klin (Munich)       Date:  1999-11-15

Review 4.  Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis.

Authors:  Sandra Baumgart; Volker Ellenrieder; Martin E Fernandez-Zapico
Journal:  Gut       Date:  2011-10-13       Impact factor: 23.059

5.  Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer.

Authors:  C A Maurer; M M Borner; J Läuffer; H Friess; K Z'graggen; J Triller; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-06

6.  Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.

Authors:  Keiichi Suzuki; Koichi Aiura; Sachiko Matsuda; Osamu Itano; Osamu Takeuchi; Kazuo Umezawa; Yuko Kitagawa
Journal:  Clin Exp Metastasis       Date:  2012-10-31       Impact factor: 5.150

7.  A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Authors:  S Cascinu; R R Silva; S Barni; R Labianca; L Frontini; E Piazza; G Pancera; P Giordani; L Giuliodori; M A Pessi; V Fusco; G Luporini; R Cellerino; G Catalano
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

8.  Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

Authors:  M Reni; L Pasetto; G Aprile; S Cordio; E Bonetto; S Dell'Oro; P Passoni; L Piemonti; C Fugazza; G Luppi; C Milandri; R Nicoletti; A Zerbi; G Balzano; V Di Carlo; A A Brandes
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

9.  Retinoic acid receptor alpha mediates growth inhibition by retinoids in rat pancreatic carcinoma DSL-6A/C1 cells.

Authors:  F H Brembeck; A Kaiser; K Detjen; H Hotz; T Foitzik; H J Buhr; E O Riecken; S Rosewicz
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

10.  A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

Authors:  A Mercalli; V Sordi; R Formicola; M Dandrea; S Beghelli; A Scarpa; V Di Carlo; M Reni; L Piemonti
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.